TBNTech
Exercise in a pill
Publication: MIT Technology Review
Author: Cassandra Willyard
Source published: 21/10/2026, 09:00:00 UTC
Briefing created: 21/10/2026, 09:14:47 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 21/10/2026, 09:05:24 UTC.
Briefings
Researchers at the University of Florida and Cambrian Bio are developing drugs to mimic exercise benefits, targeting a receptor always active in muscle cells. A key finding is that a drug developed by Burris increased receptor activity in mice, resulting in longer running distances without physical exertion. Additionally, Cambrian Bio's drug ATX-304 successfully reduced liver and belly fat in obese individuals while boosting metabolism. Despite promising preclinical results, the FDA does not approve wellness-enhancing drugs, and over 90% of human trials fail. The study focuses on treating frailty and chronic illness but acknowledges significant regulatory and experimental hurdles.
Key points
- A drug developed by Burris increased a specific receptor's activity in muscle cells, allowing mice to run longer distances without physical exercise.
- Cambrian Bio's drug ATX-304 reduced liver and belly fat in obese individuals while boosting metabolism to help sustain physical activity.
Context
Researchers aim to create medicines that mimic exercise benefits for those with frailty or chronic illness, addressing the high failure rate of wellness drugs. The study leverages a receptor that remains active regardless of exercise, with Cambrian Bio's drug showing promise in reducing metabolic issues in obese subjects.
Limitations
Evidence is limited to preclinical mouse studies and one human trial; the FDA does not approve wellness drugs, and over 90% of human trials fail. The study remains in development, with significant regulatory and experimental hurdles remaining.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 21/10/2026, 09:14:47 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeibpgptdorpoyiwourocesfmbe65nhbczodqpam6ciid7t6pmzqvaa